2021

• Delbue D, Lebenheim L, Cardoso-Silva D, Dony V, Krug SM, Richter JF, Manna S, Munoz M, Wolk K, Heldt C, Heimesaat M, Sabat R, Siegmund B, Schumann M (2021) Reprogramming intestinal epithelial cell polarity by interleukin-22. Front. Med. (Lausanne) 8: 656047. doi: 10.3389/fmed.2021.656047 (IF 5.1)

2019

• Delbue D, Cardoso-Silva D, Branchi F, Itzlinger A, Letizia M, Siegmund B, Schumann M (2019) Celiac disease monocytes induce a barrier defect in intestinal epithelial cells. Int. J. Mol. Sci. 20(22): 5597 (12 pages) [PubMed] [WebPage] [PDF] (IF 4.6)

  • Review

• Cardoso-Silva D*, Delbue D* (*shared first authorship), Itzlinger A, Moerkens R, Withoff S, Branchi F, Schumann M (2019) Intestinal barrier function in gluten-related disorders. Nutrients 11(10): 2325 (19 pages) [PubMed] [WebPage] [PDF] (IF 4.6)

2013 - 2016

• Lemos LG, Nestal de Moraes G, Delbue D, Vasconcelos Fda C, Bernardo PS, Lam EW, Buarque CD, Costa PR, Maia RC (2016) 11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes. J. Cancer Res. Clin. Oncol. 142(10): 2119-2130 (IF 3.5) [PubMed] [WebPage] [PDF]

• Nestal de Moraes G, Delbue D, Silva KL, Robaina MC, Khongkow P, Gomes AR, Zona S, Crocamo S, Mencalha AL, Magalhães LM, Lam EW, Maia RC (2015) FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. Cell Signal. 27(12): 2496-2505 (IF 4.2) [PubMed] [WebPage] [PDF]

• Nestal de Moraes G, Khongkow P, Gong C, Yao S, Gomes AR, Ji Z, Kandola N, Delbue D, Man EP, Khoo US, Sharrocks AD, Lam EW (2015) Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer. Oncogenesis 4: e167 (IF 5.0) [PubMed] [WebPage] [PDF]

• Nestal de Moraes G, Vasconcelos FC, Delbue D, Mognol GP, Sternberg C, Viola JP, Maia RC (2013) Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels. Eur. J. Cell Biol. 92(8-9): 247-256 (IF 3.7) [PubMed] [WebPage] [PDF]

Back